Mathematical Modelling for Patient Selection in Proton Therapy |
| |
| Affiliation: | 1. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK;2. The Christie NHS Foundation Trust, Manchester, UK;3. NIHR Manchester Biomedical Research Centre, Manchester University, Manchester Academic Health Science Centre, Manchester, UK;1. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana;2. Indiana University Health Proton Therapy Center, Bloomington, Indiana;1. Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom;2. Proton Therapy Center Czech s.r.o., Prague, Czech Republic;3. Manchester Cancer Research Centre, Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom;4. CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom;5. Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;1. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland;2. Department of Internal Medicine, University of Maryland School of Medicine, Baltimore, Maryland;3. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland;4. Miami Cancer Institute at Baptist Health South Florida, Miami, Florida;1. Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, The Netherlands;2. European Institute of Oncology, Milan, Italy;3. Department of Oncology, Laboratory of Experimental Radiotherapy, KU Leuven – University of Leuven & Department of Radiation Oncology, University Hospitals Leuven, Belgium;4. Department of Radiation Oncology, University of Tübingen, Germany;5. Department of Radiation Oncology and Medical Physics, University Hospital of Grenoble Alpes (CHU-GA), France;6. France HADRON National Research Infrastructure, IPNL Lyon, France;7. University Grenoble Alpes, France;8. European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium;9. Radiation Oncology Department, Ghent University Hospital and Ghent University, Belgium;10. Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, CH-5232 Villigen, Switzerland;11. Department of Radiation Oncology, University Hospital of Bern, Switzerland;12. Department of Oncology, Aarhus University Hospital, Denmark;13. OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz ZentrumDresden Rossendorf, Germany;14. Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany;15. Helmholtz-Zentrum Dresden – Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany;1. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey;2. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York;3. Department of Radiation Oncology, George Washington University Hospital, Washington, District of Columbia;4. Department of Radiation Oncology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey;1. Department of Radiation Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;2. Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;6. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;5. Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania;3. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania;4. The Wharton School and Penn Medicine Center for Health Care Innovation, University of Pennsylvania, Philadelphia, Pennsylvania |
| |
| Abstract: | Proton beam therapy (PBT) is still relatively new in cancer treatment and the clinical evidence base is relatively sparse. Mathematical modelling offers assistance when selecting patients for PBT and predicting the demand for service. Discrete event simulation, normal tissue complication probability, quality-adjusted life-years and Markov Chain models are all mathematical and statistical modelling techniques currently used but none is dominant. As new evidence and outcome data become available from PBT, comprehensive models will emerge that are less dependent on the specific technologies of radiotherapy planning and delivery. |
| |
| Keywords: | Discrete event simulation mathematical modelling NTCP patient selection proton therapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
